BLINKLAB Ltd, a smartphone-based AI diagnostic tools for autism company, has announced a new partnership with the US Turning Pointe Autism Foundation.
The aim is to initiate a clinical study focused on enhancing autism diagnostics in children.
This strategic move will utilise BlinkLab's technology to conduct a study involving 200 children - 100 previously diagnosed with autism and 100 without.
CEO Henk-Jan Boele said, "our partnership with Turning Pointe is more than just collaboration".
"It is a major step toward fulfilling our mission to make well-established neurobehavioural testing clinically accessible and efficient."
Chair Brian Leedman added that he expects more such announcements ahead of the start of its FDA registration study later this year.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 May 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 May 24
